BACKGROUND: A 2-stage ovarian cancer screening strategy was evaluated that incorporates change of carbohydrate antigen 125 (CA125) levels over time and age to estimate risk of ovarian cancer. Women with high-risk scores were referred for transvaginal ultrasound (TVS). METHODS: A single-arm, prospective study of postmenopausal women was conducted. Participants underwent an annual CA125 blood test. Based on the Risk of Ovarian Cancer Algorithm (ROCA) result, women were triaged to next annual CA125 test (low risk), repeat CA125 test in 3 months (intermediate risk), or TVS and referral to a gynecologic oncologist (high risk). RESULTS: A total of 4051 women participated over 11 years. The average annual rate of referral to a CA125 test in 3 months was 5.8%, and the average annual referral rate to TVS and review by a gynecologic oncologist was 0.9%. Ten women underwent surgery on the basis of TVS, with 4 invasive ovarian cancers (1 with stage IA disease, 2 with stage IC disease, and 1 with stage IIB disease), 2 ovarian tumors of low malignant potential (both stage IA), 1 endometrial cancer (stage I), and 3 benign ovarian tumors, providing a positive predictive value of 40% (95% confidence interval = 12.2%, 73.8%) for detecting invasive ovarian cancer. The specificity was 99.9% (95% confidence interval = 99.7%, 100%). All 4 women with invasive ovarian cancer were enrolled in the study for at least 3 years with low-risk annual CA125 test values prior to rising CA125 levels. CONCLUSIONS: ROCA followed by TVS demonstrated excellent specificity and positive predictive value in a population of US women at average risk for ovarian cancer.
BACKGROUND: A 2-stage ovarian cancer screening strategy was evaluated that incorporates change of carbohydrate antigen 125 (CA125) levels over time and age to estimate risk of ovarian cancer. Women with high-risk scores were referred for transvaginal ultrasound (TVS). METHODS: A single-arm, prospective study of postmenopausal women was conducted. Participants underwent an annual CA125 blood test. Based on the Risk of Ovarian Cancer Algorithm (ROCA) result, women were triaged to next annual CA125 test (low risk), repeat CA125 test in 3 months (intermediate risk), or TVS and referral to a gynecologic oncologist (high risk). RESULTS: A total of 4051 women participated over 11 years. The average annual rate of referral to a CA125 test in 3 months was 5.8%, and the average annual referral rate to TVS and review by a gynecologic oncologist was 0.9%. Ten women underwent surgery on the basis of TVS, with 4 invasive ovarian cancers (1 with stage IA disease, 2 with stage IC disease, and 1 with stage IIB disease), 2 ovarian tumors of low malignant potential (both stage IA), 1 endometrial cancer (stage I), and 3 benign ovarian tumors, providing a positive predictive value of 40% (95% confidence interval = 12.2%, 73.8%) for detecting invasive ovarian cancer. The specificity was 99.9% (95% confidence interval = 99.7%, 100%). All 4 women with invasive ovarian cancer were enrolled in the study for at least 3 years with low-risk annual CA125 test values prior to rising CA125 levels. CONCLUSIONS:ROCA followed by TVS demonstrated excellent specificity and positive predictive value in a population of US women at average risk for ovarian cancer.
Authors: Usha Menon; Steven J Skates; Sara Lewis; Adam N Rosenthal; Barnaby Rufford; Karen Sibley; Nicola Macdonald; Anne Dawnay; Arjun Jeyarajah; Robert C Bast; David Oram; Ian J Jacobs Journal: J Clin Oncol Date: 2005-11-01 Impact factor: 44.544
Authors: Saundra S Buys; Edward Partridge; Mark H Greene; Philip C Prorok; Douglas Reding; Thomas L Riley; Patricia Hartge; Richard M Fagerstrom; Lawrence R Ragard; David Chia; Grant Izmirlian; Mona Fouad; Christine C Johnson; John K Gohagan Journal: Am J Obstet Gynecol Date: 2005-11 Impact factor: 8.661
Authors: Usha Menon; Aleksandra Gentry-Maharaj; Rachel Hallett; Andy Ryan; Matthew Burnell; Aarti Sharma; Sara Lewis; Susan Davies; Susan Philpott; Alberto Lopes; Keith Godfrey; David Oram; Jonathan Herod; Karin Williamson; Mourad W Seif; Ian Scott; Tim Mould; Robert Woolas; John Murdoch; Stephen Dobbs; Nazar N Amso; Simon Leeson; Derek Cruickshank; Alistair McGuire; Stuart Campbell; Lesley Fallowfield; Naveena Singh; Anne Dawnay; Steven J Skates; Mahesh Parmar; Ian Jacobs Journal: Lancet Oncol Date: 2009-03-11 Impact factor: 41.316
Authors: Steven J Skates; Usha Menon; Nicola MacDonald; Adam N Rosenthal; David H Oram; Robert C Knapp; Ian J Jacobs Journal: J Clin Oncol Date: 2003-05-15 Impact factor: 44.544
Authors: Tzu-Fang Lou; Deepa Sethuraman; Patrick Dospoy; Pallevi Srivastva; Hyun Seok Kim; Joongsoo Kim; Xiaotu Ma; Pei-Hsuan Chen; Kenneth E Huffman; Robin E Frink; Jill E Larsen; Cheryl Lewis; Sang-Won Um; Duk-Hwan Kim; Jung-Mo Ahn; Ralph J DeBerardinis; Michael A White; John D Minna; Hyuntae Yoo Journal: Cancer Prev Res (Phila) Date: 2015-10-28
Authors: Archana R Simmons; Evangelia Ourania Fourkala; Aleksandra Gentry-Maharaj; Andy Ryan; Margie N Sutton; Keith Baggerly; Hui Zheng; Karen H Lu; Ian Jacobs; Steven Skates; Usha Menon; Robert C Bast Journal: Cancer Prev Res (Phila) Date: 2019-04-09
Authors: Stacey J Winham; Sebastian M Armasu; Mine S Cicek; Melissa C Larson; Julie M Cunningham; Kimberly R Kalli; Brooke L Fridley; Ellen L Goode Journal: Genet Epidemiol Date: 2014-05-22 Impact factor: 2.135
Authors: Amy P N Skubitz; Kristin L M Boylan; Kate Geschwind; Qing Cao; Timothy K Starr; Melissa A Geller; Joseph Celestino; Robert C Bast; Karen H Lu; Joseph S Koopmeiners Journal: Cancer Prev Res (Phila) Date: 2019-02-01
Authors: Felix Leung; Marcus Q Bernardini; Marshall D Brown; Yingye Zheng; Rafael Molina; Robert C Bast; Gerard Davis; Stefano Serra; Eleftherios P Diamandis; Vathany Kulasingam Journal: Cancer Epidemiol Biomarkers Prev Date: 2016-07-22 Impact factor: 4.254